Proteolysis‐targeting chimeras in drug development: A safety perspective

Proteolysis‐targeting chimeras are a new drug modality that exploits the endogenous ubiquitin proteasome system to degrade a protein of interest for therapeutic benefit. As the first‐generation of proteolysis‐targeting chimeras have now entered clinical trials for oncology indications, it is timely...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Br J Pharmacol
Prif Awduron: Moreau, Kevin, Coen, Muireann, Zhang, Andrew X., Pachl, Fiona, Castaldi, M. Paola, Dahl, Goran, Boyd, Helen, Scott, Clay, Newham, Pete
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2020
Pynciau:
Review Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7070175/
https://ncbi.nlm.nih.gov/pubmed/32022252
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.15014
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg